No products in the cart.
Pre-made Efungumab benchmark antibody ( scFv, anti-Heat Shock Protein 90 Homolog therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-167
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Efungumab biosimilar, scFv: Anti-Heat Shock Protein 90 Homolog therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Efungumab (trade name Mycograb) was a drug developed by NeuTec Pharma (a subsidiary of Novartis), intended to treat candidemia (a bloodstream infection caused by pathogenic yeast) in combination with amphotericin B. The European Medicines Agency has twice refused to grant marketing authorization for Mycograb, citing product safety and quality issues.
| Products Name (INN Index) | Pre-Made Efungumab biosimilar, scFv: Anti-Heat Shock Protein 90 Homolog therapeutic antibody |
|---|---|
| INN Name | Efungumab |
| Target | Heat Shock Protein 90 Homolog |
| Format | scFv |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | NA |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2006 |
| Year Recommended | 2007 |
| Companies | NeuTec Pharma |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Breast cancer,Candidiasis |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | Heat Shock Protein 90 Homolog |
| Package |
Previous slide
Next slide
